Should a patient with acute coronary syndrome receive an unfractionated heparin drip along with oral aspirin (acetylsalicylic acid) and clopidogrel (Plavix)?

Unfractionated Heparin Drip with Aspirin and Clopidogrel in Acute Coronary Syndrome

Yes, patients with acute coronary syndrome (ACS) should receive an unfractionated heparin (UFH) drip along with oral aspirin and clopidogrel (Plavix) as part of initial antithrombotic therapy. This triple therapy approach is a Class I recommendation supported by multiple high-quality guidelines and FDA labeling.

Immediate Treatment Protocol

Antiplatelet Therapy

• Aspirin: Loading dose of 150-300 mg orally (or 75-250 mg IV if oral not possible), followed by maintenance dose of 75-100 mg daily indefinitely 1, 2
• Clopidogrel: 300-600 mg loading dose, followed by 75 mg daily 1, 3
  • The FDA label specifically states Plavix should be administered "in conjunction with aspirin" for ACS 4
  • For patients needing rapid antiplatelet effect, use 600 mg loading dose 3

Anticoagulation

• UFH is recommended as standard anticoagulant during the acute phase 3, 1
• Dosing: 60-70 U/kg IV bolus (maximum 5000 U), followed by 12-15 U/kg/h infusion 5
• Target activated partial thromboplastin time (aPTT): 50-70 seconds 5
• Continue until invasive procedure or hospital discharge 1

Treatment Strategy Based on Management Approach

Early Invasive Strategy (PCI within 48 hours)

• Start all three agents immediately: aspirin, clopidogrel (consider 600 mg load), and UFH 6, 1
• Alternative anticoagulants to consider: enoxaparin or fondaparinux 1
• Ticagrelor or prasugrel may be preferred over clopidogrel if PCI is planned, but clopidogrel remains acceptable 2

Conservative/Delayed Invasive Strategy

• Triple therapy remains indicated 6, 1
• Fondaparinux may be preferable to UFH if bleeding risk is high 6
• Continue anticoagulation to hospital discharge 6

Duration of Therapy

Dual antiplatelet therapy (aspirin + clopidogrel) should continue for 12 months post-ACS unless high bleeding risk exists 3. UFH is discontinued after the acute phase (typically 2-5 days or after revascularization) 5, 1.

Critical Safety Considerations

Bleeding Risk Management

• Major bleeding increases by approximately 1% absolute risk with clopidogrel added to aspirin 6
• If PRECISE-DAPT score ≥25 (high bleeding risk), consider shortening dual antiplatelet therapy to 6 months 3
• Proton pump inhibitor recommended for patients at risk of GI bleeding 2
• Avoid omeprazole or esomeprazole with clopidogrel due to CYP2C19 interaction reducing antiplatelet effect 4

Pre-Surgical Planning

• If CABG planned, discontinue clopidogrel 5-7 days prior to surgery 5, 3
• Continue aspirin perioperatively 3
• Resume clopidogrel post-operatively as soon as safe 3

CYP2C19 Poor Metabolizers

• Clopidogrel forms less active metabolite in CYP2C19 poor metabolizers 4
• Consider alternative P2Y12 inhibitor (ticagrelor or prasugrel) in identified poor metabolizers 4

Evidence Strength

The recommendation for triple therapy is based on:

• Class I, Level A evidence from multiple contemporary guidelines 1, 3, 2
• FDA approval specifically for this indication 4
• Landmark trials (CURE, COMMIT) demonstrating 20% relative risk reduction in death/MI/stroke with clopidogrel added to aspirin 5, 6
• Historical evidence showing both aspirin and heparin reduce MI in unstable angina 7

Common Pitfalls to Avoid

1. Do not delay clopidogrel if coronary anatomy unknown and conservative strategy planned—start immediately 6, 1
2. Do not use triple therapy long-term—UFH is for acute phase only; transition to dual antiplatelet therapy 1
3. Do not combine with strong CYP2C19 inhibitors (omeprazole, esomeprazole) 4
4. Do not stop antiplatelet therapy prematurely post-stenting due to stent thrombosis risk 3

5, 6, 1, 3, 2, 4